Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Not Dead Yet: Mylan Still In Discussions With King On Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Mylan is not yet ready to declare as dead its proposed acquisition of King

You may also be interested in...



King Inventory Work-Down Plan Goal Is 1.5 Months Of On-Hand Product

Amendments to inventory management agreements with wholesalers are aimed at reducing levels to 1.5 months by the end of March. Work-down announcement accompanies King’s restatement of financials; Mylan deal remains up in the air with one week to go before walk-away date.

King Inventory Work-Down Plan Goal Is 1.5 Months Of On-Hand Product

Amendments to inventory management agreements with wholesalers are aimed at reducing levels to 1.5 months by the end of March. Work-down announcement accompanies King’s restatement of financials; Mylan deal remains up in the air with one week to go before walk-away date.

CVS' Retail Stores, PBM Will Be "Significant Participants" In Medicare – CEO

The pharmacy chain expects higher retail drug utilization under Medicare drug benefit due to employers dropping coverage for retirees who typically used mail-order pharmacies. The absence of mandatory mail provisions in the final Medicare Part D regulations is "good news," CVS says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel